The Creation of a
Comprehensive Vascular Program
within the
UC Davis Health System
-- ® --
A Distillation of Thoughts on Opportunities, Options and Issues for
Use in Ongoing Planning Discussions and Recruitments
DRAFT
Updated July 15, 2004
Prepared by the:
Office of the Associate Dean for Research
UC Davis School of Medicine
CONTENTS
3
Introduction
4
Clinical Vascular Programs
Recommendations for Clinical Program Development
7
Vascular Research Programs
Recommendations for Emphasized Research Themes
11
Vascular Education and Training Programs
12
Program Structure and Leadership
13
Existing Assets Complementing the Program
Strategic Priorities
Extramural Grants
Major Grants in Preparation
Complementary Recruitments in Departments
Endowed Chairs
15
Anticipated Resource Requirements
APPENDICES
17
18
21
Appendix A. Strategic Priorities
Appendix B. Extramural Grants in Vascular-Related Areas
Appendix C. UC Davis Medical Center Facilities
2
INTRODUCTION
Anticipating that scientific and technological advances will significantly transform the diagnosis
and treatment of vascular diseases in the next decades, the UC Davis Health System (UCDHS)
began exploring the creation of a comprehensive vascular program in late 2002. The goal of the
program is to substantially enhance our clinical, research and education activities related to
vascular diseases under nationally prominent leadership. The multi-disciplinary program’s
organizational structure should furthermore facilitate the close alignment of relevant research,
clinical service and education activities among relevant departments. We recognize that
enhancing our capabilities and reputational standing in vascular biology and medicine may
require significant investments in additional faculty and infrastructure.
A draft description of what was earlier referred to as a “UC Davis Vascular Institute” was
prepared by Richard Latchaw, M.D. and a faculty steering committee in the Fall, 2002 and
discussed with UCDHS leadership later that year. The draft enumerated a large menu of
potential program components, drawn from relevant clinical and research programs at UC Davis
that were either solidly established or in need of development. The decision was made to seek
external consultations to help identify which components should be strategically emphasized for
development, what resources would be required, how the administrative structure should be
aligned, and which individuals with proven track records for building successful, interactive
clinical and research programs, should be considered for senior leadership positions.
This white paper draws on the input of four external consultations1 and additional internal
discussions since 2002. It also summarizes pertinent institutional information on existing clinical
and research strengths in the vascular arena at UC Davis. The overall purpose of this document
is to distill our current thinking about the potential opportunities and options (including program
focus, structure and leadership) for a new comprehensive vascular program in the UCDHS. It is
intended to provide a platform for continued discussions to further refine our planning and
recruitment efforts.
1
Pascal Goldschmidt, MD, Chief of Cardiology, Duke University Medical Center;
Kenneth Chien, MD, Director, Institute of Molecular Medicine, UC San Diego;
Donald Bers, PhD, Chair of Physiology, Stritch School of Medicine, Loyola University, Chicago; and
John Laird, MD, Director of Peripheral Vascular Interventions, Cardiovascular Research Institute, Washington
Hospital Center, Washington, DC
3
CLINICAL VASCULAR PROGRAMS
Academic tertiary medical centers generally recognize that excellence in cardiac services is
essential to the overall quality of their research, education and public service missions. Cardiac
services also represent a large and well-funded market and a significant source of revenue for
supporting academic programs.
The very high level of cardiovascular services provided by other hospital systems in
Sacramento creates an intensely competitive market environment. However, the region’s strong
population growth, as well as the rapid evolution of minimally-invasive diagnostic and treatment
procedures, affords the UC Davis Health System (UCDHS) an opportunity to gain substantial
market share. Coupled with successful strategic investments in clinically-focused research,
UCDHS could eventually assume a clear leadership position in the region.
An important step in enhancing the cardiac program was the recruitment, in late 2000, of Dr.
Reginald Low from a competing hospital system to serve as Chief of the UCDHS Division of
Cardiovascular Medicine. Dr. Low is an internationally renowned interventional cardiologist with
a strong clinical practice and active research in developing minimally invasive cardiac
procedures and devices for coronary artery revascularization, including PCTA and stenting. His
interests also include enabling imaging technologies, such as electron beam ultrafast CT, new
generation helical CT and magnetic resonance CT. Subsequent to his recruitment, the Health
System invested in two new state-of-the art cardiac catheterization suites as part of an overall
plan to upgrade and expand cardiac services.
In 2001, UCDHS also recruited Dr. Richard Latchaw from the University of Pittsburgh to the
Department of Radiology. Dr. Latchaw is a clinician-scientist whose clinical expertise focuses on
interventional cerebrovascular neuroradiology. His research activities, which have generated
two patents, include the development of devices for aneurysm occlusion and catheters for acute
stroke treatment, including MR-compatible catheters, and the use of stem cells imbedded in
stents and catheters to stimulate angiogenesis.
Drs. Low and Latchaw provide a foundation for the development of a comprehensive,
multidisciplinary, interventional vascular program encompassing cardiovascular,
cerebrovascular and peripheral vascular diseases. Additional steps to building a regionally
preeminent comprehensive clinical program need further consideration and evaluation. The
major questions include:
ÿ Do we have appropriate leadership and sufficient clinical capacity in the
cardiovascular, neurovascular and peripheral vascular areas to achieve distinction in
our market area?
ÿ Do we have sufficient physician coverage and clinic capacity in disciplines that would
refer patients into the interventional vascular program?
ÿ What is the appropriate balance we should achieve in CV surgery, interventional
cardiology, and non-interventional cardiology?
ÿ Similarly, what are the appropriate balances we should achieve between
interventionalists, non-interventionalists and surgeons for cerbrovascular and
peripheral vascular care?
ÿ What differentiating technologies and overall financial resources are required to build
a distinguished and market-leading clinical program?
ÿ What is the best organizational structure for building an efficient, multidisciplinary
clinical program?
4
RECOMMENDATIONS FOR CLINICAL PROGRAM DEVELOPMENT
Two of four external consultants offered specific recommendations regarding the clinical side of
the proposed program.
Dr. Goldschmidt: During his March, 2003 site visit, Duke University’s then Chief of Cardiology
(now Chair of Internal Medicine), Dr. Pascal Goldschmidt, noted that UCDHS has existing
outstanding programs in highly competitive clinical disciplines such as interventional cardiology,
interventional radiology and vascular surgery. His specific recommendations for further
enhancements were:
ÿ Differentiating Technologies: Acquiring additional “differentiating technologies”
and associated expertise would help differentiate UCDHS from competing
providers and be attractive to patients. Examples include cardiac MRI, CT
angiography, heart failure and other multi-faceted technologies. Under the
collaborative clinical leadership of Drs. Low and Latchaw, such technologies
could substantially contribute to building a highly competitive multidisciplinary
interventional vascular program at UCD.
ÿ Multidisciplinary Approach: Eliminate departments’ silos and bridge
multidisciplinary programs that are seamless across the usual academic
organizational boundaries.
ÿ Clinician Recruitments: Aggressively recruit clinicians who will, in the long run,
contribute directly or indirectly to enhancing the volumes of interventional
vascular procedures. General cardiologists also will need to be recruited (even if
they do not provide enough RVUs to pay their salaries) to ensure the
comprehensiveness of the program and to provide referrals for well-reimbursed
procedures (e.g., CT-surgery, coronary PCI).
Dr. Laird: Following a September 2003 site visit, Dr. John Laird, director of Peripheral Vascular
Interventions at Washington Hospital Center and Clinical Assistant Professor at Georgetown
University Medical Center, endorsed the establishment of clinical programs related to
innovative, minimally-invasive techniques for the treatment of a variety of vascular conditions. In
his opinion, this approach would quickly establish UCDHS as the recognized “place to go” for
cutting-edge vascular interventions in Northern California. Dr. Laird presented the following
additional recommendations and related issues for clinical program development:
ÿ Structure: Recommended the recruitment of a Clinical Director of the Vascular
Program, who would co-direct the overall program in partnership with a Research
Director. (See additional comments in the section on Program Structure and
Leadership.)
ÿ Clinical Leadership: Based on his opinion that Sacramento/Northern California
suffers from a “vacuum” of cardiologists with recognized expertise in peripheral
vascular interventions, Laird recommended the recruitment of such an individual
as the Clinical Director. The combination of such an individual with Dr. Low,
would help rapidly grow interventional cardiac and vascular patient volumes in
the UCDHS. The role of the Clinical Director should be to support the growth and
development of vascular interventions in Vascular Surgery and Interventional
Radiology, as well as in Cardiology. Consequently, this individual must be a
“bridge builder” who can foster cooperation among various vascular specialists. A
successful Comprehensive Vascular Program will provide sufficient growth in
new patients to benefit all.
ÿ Multidisciplinary Clinic: An outpatient Vascular Center should be established
where Vascular Surgery, Interventional Radiology/Neuroradiology and
Interventional Cardiology could see patients together in a multidisciplinary
5
setting. This would help reinforce multidisciplinary cooperation and set UCDHS
apart from other institutions.
ÿ Cutting-edge Vascular Interventions: In a multidisciplinary environment, vascular
specialists at UCDHS should collaboratively establish programs in new
techniques to prevent/treat stroke, carotid stenting, endovascular stenting for
AAA and thoracic aortic disorders, innovative limb salvage techniques, etc.
ÿ Clinical Resource Issues—AC and IC Beds: The availability of sufficient acute
care and intensive care beds at UCD Medical Center must be addressed for an
interventional vascular program to succeed. To establish and maintain new
referral lines, there cannot be roadblocks to prompt patient transfers from other
institutions. The shortage of intensive care beds was reported to have hindered
earlier plans to initiate an Acute Stroke Intervention program within Interventional
Neuroradiology.
ÿ Clinical Resource Issues—Cath Labs: Attracting an interventional cardiologist
with expertise in peripheral vascular intervention will require either the
modification of an existing cardiac catheterization labs or construction of a new
lab with peripheral vascular imaging capabilities. While existing labs at UCD
Medical Center are state-of-the art, they are not well-suited for peripheral
vascular use. High quality MR angiography and CT angiohraphy systems are
needed for non-invasive evaluation of vascular patients. Several vendors,
including Phillips, now offer “hybrid” cath lab units that can be used for both
coronary and peripheral vascular diagnostics and interventions. Current plans for
the construction of new cath labs in the hospital tower in 2006 or 2007 will
present an obstacle to the timely establishment of a first class program.
6
VASCULAR RESEARCH PROGRAMS
Establishing a successful, academically-based program in vascular care requires that key
clinical and research strengths be sufficiently aligned to ensure synergy and a productive
translational research pathway. Functional bridges between groups of basic and clinical
researchers are a prerequisite for “high impact” science leading to advances in clinical care.
Historically, UC Davis has had difficulty in building such bridges, suggesting the need to also
consider appropriate enabling organizational structures and leadership.
RECOMMENDATIONS FOR EMPHASIZED RESEARCH THEMES
The question of which subsets of vascular research themes posed the greatest opportunities for
a UC Davis Comprehensive Vascular Program was addressed by all four consultants, as well as
internal scientific leaders. The following section summarizes discussions of the alternatives thus
far considered.
Vascular Applications of Stem Cells: Dr. Goldschmidt, made a strong case for building a
basic / translational research theme around the cardiac and peripheral vascular applications of
stem cells. His recommendation was premised on the judgement that, while excitement over
vascular applications of stem cells was building, the field is still relatively under-populated,
allowing the opportunity for a stem-cell focused vascular research program to have “high
impact.” He cited the opportunity for this theme to attract substantial NIH funding, lead to
innovative phase I-III trials and provide multiple opportunities for interaction between clinicians
and more basic translational researchers from multiple departments. This approach, he argued,
could benefit from existing UCD resources in animal models, biomedical engineering, cell
biology, receptor biology, membrane biology, and the biology of cellular and tissue injury. Dr.
Goldschmidt noted that it would be necessary to launch this effort in parallel with a broader
effort to enhance stem cell expertise at UC Davis. The planned stem cell/ regenerative medicine
thrust of the joint research program at the Shriners Hospital, Sacramento (with up to nine
additional investigator recruits), as well as a recent Health System initiative to create a new
multi-department stem cell program with four new faculty positions (see below) would eventually
provide a larger stem cell investigator community at UCD in which a more focused vascular
stem cell program could flourish. A 2003 agreement to explore collaborative research themes
with the Childrens’ Hospital Oakland Research Institute, or CHORI (which has an existing stem
cell program) could further facilitate the development of a broader UCD stem cell program.
Further evaluation of the stem cell theme was obtained from Dr. Kenneth Chien, Professor of
Medicine and Director of the Institute of Molecular Medicine at UC San Diego. Dr. Chien is coleader, with Dr. Fred (Rusty) Gage at the Salk Institute, of a regenerative medicine program that
includes, a strong focus on applications of stem cells in vascular medicine. Chien pointed to a
key ingredient at Davis that other institutions lacked, namely the ability to use primate models
for translational stem cell research. He indicated that primate models could be a key basis for
collaboration between Davis and UCSD (and by extension, UCSF and other major programs).
He cautioned, however, that while stem cells hold significant promise for clinical applications,
they offer only that – just a promise at this stage.
Initial internal discussions of a potential stem cell focus pointed out that it constitutes a
methodology-driven (rather than hypothesis-driven) theme which is sufficiently exciting to
explore with additional investments, but perhaps too risky to form the sole thrust of the
Comprehensive Vascular Programs’ basic/translational research agenda. UC Davis has one
existing investigator with significant funding and national reputation in the stem cell arena (Dr.
Tarantal, Pediatrics), who coincidentally could be viewed as a potential leader of this theme.
She is the PI on the NIH-funded Center for Fetal Monkey Gene Transfer for Heart, Lung and
Blood Diseases. However, our overall programmatic depth in stem cells is still relatively shallow
7
at present and would require significant time and resources to build to preeminent stature. A
new stem cell initiative led by the departments of Pediatrics, Cell Biology and Pathology, has
four faculty FTE positions under recruitment. Even with additional positions jointly recruited at
the Shriners Hospital, a significant stem cell community that would provide an intellectually
supportive environment for a focused program on vascular applications will take several years
to develop at UC Davis. Consequently, current internal opinions lean toward regarding a
program in vascular applications of stem cells as an important longer-term investment in a
component of a vascular research agenda, rather than the core or primary research focus at this
time. External consultant Laird is also in agreement with this view.
Differentiating Clinical Technologies: In addition to a more basic and translationally-oriented
stem cell program, Dr. Goldschmidt believed UCDHS should pursue clinical research
opportunities in “differentiating technologies” with the recruitment of additional experts. Given
Dr. Latchaw’s expertise in cerebrovascular imaging, Goldschmidt specifically suggested
recruitments in the technologies previously noted (cardiac MR imaging, CT angiography, heart
failure and other multifaceted technologies). It was subsequently noted in internal discussions
that technology-based research could build upon the expertise of the UCD Research Imaging
Center (Dr. Cameron Carter), imaging technology-oriented faculty in the UCD Department of
Biomedical Engineering, and potential collaborators at SRI International and the Lawrence
Livermore National Laboratory.
Developmental Research on Innovative Vascular Interventions:
Dr. Laird noted that building a world-class Vascular Program requires strength on both the
clinical and research sides and a leadership that reflects the importance of both. To bridge a
clinical program focused on cutting-edge vascular interventions with the basic research
initiative, it will be important to support the testing and development of new devices in the
coronary and peripheral vasculature and further develop partnerships with groups such as SRI
International or the Lawrence Livermore National Laboratory. If space permits, an appropriately
equipped lab in the Research Imaging Center would provide synergy with ongoing research in
advanced imaging modalities such as high resolution MR and ultrafast CT. To support
developmental or translational research on vascular interventions will require building or
expanding the capability for large animal research with a large animal catheterization laboratory
with the capability for high quality fluoroscopic and digital imaging. Dr. Laird also noted that the
concept of a unifying basic research theme in “Protection and Recovery from Vascular
Injury/Disease” (see below) would dovetail nicely with areas currently of great interest in the
field of vascular interventions, including drug eluting stents, methods to inhibit intimal
hyperplasia and vulnerable plaque. He was also in agreement with the concept of stem cells
being an important component, but not the primary focus, of a vascular research agenda.
Protection and Recovery from Vascular Injury / Disease:
To assess additional, and perhaps more immediate, opportunities for “high impact” translational
research in the vascular area, Associate Dean for Research Roy Curry undertook an evaluation
of our already sizeable base of NHLBI-funded and related projects. Current NIH funding to the
Health System shows that after the National Cancer Institute, our largest block of funding comes
from the National Heart, Lung and Blood Institute (NHLBI). UCDHS’s total NIH funding from the
NHLBI and other institutes supporting vascular-related studies is $8.1 million from 33 grants,
representing approximately 13% of our total NIH support). An additional 40 grants from other
non-NIH sources contribute another $2.9 million annually to vascular-related research. (See list
of NIH and other extramural grants in Appendix B.) Combined, the UCDHS has 41 funded
investigators with 73 awards totaling $11million in annual “vascular” funding. These grants data
excludes non-Health System/School of Medicine UC Davis faculty, some of whom collaborate
with UCDHS faculty.
8
Given that, unlike our Cancer Programs, we have no existing center structure in vascular
biology/medicine, these figures are truly impressive and suggest that we consider developing
additional basic/translational research themes from a base of existing strength.
Given the areas emphasized by existing investigators, “Protection and Recovery from Vascular
Injury / Disease” emerges as a potentially unifying theme. With appropriate investment,
organization and leadership this theme could, in a more immediate time-frame, establish a
preeminent basic/translational research program within the Comprehensive Vascular Program.
At the basic research level, one of the most promising initiatives that directly links to the
“protection and recovery” theme is membrane biology, where the Department of Human
Physiology has existing strong programs and where both Physiology and Pharmacology are
recruiting new faculty. These recruitments are building a critical mass of expertise in cellular,
molecular and genomic approaches to investigate: 1) ion channels controlling nerve and
vascular function, and 2) membrane transporters controlling a variety of cellular functions
including cell volume, pH, and ionic composition. These membrane-oriented topics are closely
linked to mechanisms underlying a variety of vascular cell and tissue injuries that presage the
onset of major vascular disease. Such injuries may be caused by hypoxia, acute and chronic
inflammation, reperfusion, exposure to infectious agents and dietary and life-style factors.
Expertise in the function of cardiac muscle, vascular smooth muscle, leukocytes and vascular
endothelial cells will be substantially strengthened by growth in the membrane biology program.
Further, as our base of stem cell biologists grows through initiatives already planned, additional
enhancements to develop a vascular-focused stem cell program could follow at an appropriate
time.
Clinical research on protection from vascular injury/disease could focus on developing
strategies for modifying blood vessel inflammatory responses and the ion channel regulation of
blood flow and cell survival. Given existing strengths in Epidemiology and Preventive Medicine,
and the Center for Health Services Research, there are opportunities for population-based
studies of vascular disease protection and prevention as well.
Clinically, recovery from vascular injury initially could encompass the development and
refinement of cardiac and cerebrovascular minimally-invasive interventions, including clinical
trials of new devices and related pharmaceuticals, including drug-eluting stents to restore
perfusion. Appropriate topics for clinical studies include the factors determining restenosis and
vessel injury after stent placement, stent viability and the effects of eluted drugs on the viability
of distal cells. Potentially complementary avenues of clinical investigation may involve the use of
injected growth factors and stem cells to restore muscle and nerve cell function and to stimulate
blood vessel regrowth.
Dr. John Laird noted that the “Protection and Recovery” theme would dovetail nicely with a
clinical research focus in vascular interventions, particularly areas of greatest interest, such as
drug eluting stents, methods to inhibit intimal hyperplasia, and vulnerable plaques. He also
pointed out that the theme lent itself to being marketed to the general public as “Promoting
Vascular Health” and would need to continue to focus research on the management of lipid
disorders and the role of risk factor/lifestyle modifications on the progression of vascular
disease.
Combination of Vascular and Myocardial Research Themes: Loyal University/ Stritch
School of Medicine’s Chair of Physiology, Dr. Donald Bers, argues that the specific research
themes of a new Vascular Program would be significantly less important than the quality and
9
stature of the scientific leadership that would be hired. Noting that most of the existing
cardiovascular institutes in the country have either cardiac or vascular strengths, but not both,
he suggests that UCDHS might develop a unique program that develops strengths in both
areas. While stating that an initial research focus at UCDHS could be in any of several research
areas (e.g., cardiac physiology, vascular biology, hypertrophic signaling, etc.), Bers advocates
eventually developing multiple nationally recognized research foci in a staged fashion. The
Vascular Program’s initial research focus should be immediately nucleated by the recruitment of
an internationally recognized scientific leader who, in a “package” recruitment, would endeavor
to bring an established research team to UCD, comprised of members of the leader’s own
laboratory as well as several faculty-level colleagues with whom the leader frequently interacts.
Appropriate existing UCD scientists who fit into the initial focus area could also be brought into
the research program during the first phase of development. A second, complementary, area of
research could be built initially with mostly existing UCD talent incorporated into the program. A
second phase of development would include a second round of faculty recruitment to enrich the
second focus area to a comparable state of prominence as the first, and also patch strategic
areas that might be limiting the progress of the initial focus. Bers suggests that an initial focus
might be in cardiac cellular electrophysiology and excitation-contraction coupling, and cellular
and molecular mechanisms of heart failure. In addition to new recruits, this theme could draw
upon several people at UCD (possibly Drs. N. Chiamvimonvat, A. Knowlton, P. Cala, S.
Anderson, H. Liu, I. Pessah and others) to build a scientific critical mass. The development of a
vascular group could comprise another focus area. This theme (in addition to future, phase 2
recruits) could draw upon existing talent including Drs. J. Rutledge, F.E. Curry, S. Simon, and A.
Knowlton. In a “steady state” the overall program’s research agenda should have two to three
identifiable foci of strength.
10
VASCULAR EDUCATION & TRAINING PROGRAMS
Clinician Training: Once UCDHS becomes recognized as a Center of Excellence for vascular
imaging and minimally invasive vascular interventions, the Comprehensive Vascular Program
could become a training center for vascular specialists interested in new, minimally-invasive
techniques. In the opinion of Dr. Laird, the UCDMC is uniquely positioned to become a leader in
physician education and training, strengthened by the introduction of the Sim-Suite (simulated
patient suite) and expertise that is present in robotic surgery. The likely approval of carotid
stenting by the FDA in the next year will likely generate immediate need for training for
physicians interested in this technique.
Clinician-Scientist Training: Dr. Bers noted that the Comprehensive Vascular Program
should target clinician-scientist training through avenues such as the MD/PhD program and
program-sponsored Research Fellowships in clinical departments.
Complementing this effort, we note that UCDHS initiated (June, 2004) a “Mentored Clinical
Research Program” (MCRTP) focused on junior faculty, clinical fellows and advanced
postdoctoral fellows interested in developing careers in patient-focused research. The program
entails a two-year multidisciplinary curriculum of didactic instruction, workshops, seminars and
other special activities. Annual enrollments will be 10-12 students. Work is proceeding well to
establish a new Masters Degree in Clinical Research at UC Davis as part of the development of
this program. A K30 application has been submitted to the NIH for further support of the MCRTP
beginning in 2005.
Graduate Education: Graduate education at UC Davis is organized around a multidepartmental Graduate Group concept. Historically, graduate education has been focused on
the west campus in Davis, but the numbers of graduate students working in laboratories in
Sacramento is increasing substantially, driven largely by recent research initiatives at the UCD
Cancer Center, and the Center for Biophotonics Science & Technology (with substantial
participation by Lawrence Livermore National Laboratory and UCD Biomedical Engineering
faculty). The development of the Joint UCD-Shriners Hospital Research Program (which is in
late stage negotiations with a director of research candidate) and the development of the
vascular research program will fuel even stronger growth in Sacramento-based graduate
education.
Medical Student Education: It is worth noting, particularly in the context of our plans to base
vascular research programs in Sacramento, that the School of Medicine is in the process of
moving its medical student teaching programs to the UC Davis Medical Center campus in
Sacramento. A new Education Building planned for 2007 in Sacramento will replace the majority
of the School’s pre-clinical education programs now housed in Tupper Hall on the Davis
campus.
11
PROGRAM STRUCTURE AND LEADERSHIP
Internal discussions have thus far favored the recruitment of separate clinical and research
leaders (most likely as co-directors) of the Comprehensive Vascular Program.
This view was also endorsed by Dr. Laird, who stated that strength on both the clinical and
research sides would be imperative in building a world-class program. As such, the program’s
leadership should reflect the importance placed in both areas. A Clinical Director and a
Research Director should form a partnership to further the goals of the overall program and help
guide the basic, clinical and translational research initiatives.
Dr. Bers favored an internationally prominent full-time researcher (without significant clinical
effort) as the overall Program Director in order to create a fundamental scientific base for
extending the work of clinical researchers to more fundamental levels, attracting more
translational researchers and creating an environment for training true clinician-scientists. For
the Director, Bers stated, it would be ideal to recruit a strong internationally recognized research
leader who has the vision, personality and ability to build a dynamic interactive research
program. Quality of leadership, rather than a specific research focus is most important.
Dr. Goldschmidt argued that a key recruit should be a clinician scientist with substantial
knowledge of both science and medicine. This individual should be determined to become a
partner for bridging the clinical and research side. In the context of the stem cell focused basic
research agenda, where preeminent full professor-level leaders will be difficult to recruit, he
recommended recruiting a talented senior Associate professor-level person from a highly
regarded program/ laboratory. Such a person, who should possess significant energy,
determination and team-skills, ideally would relish the opportunity to build a world class
program. National/international search should be developed and focused on experts from the
outside.
12
EXISTING ASSETS COMPLEMENTING THE PROGRAM
The UCDHS presents an academic environment with significant existing assets pertinent to the
consideration of a Comprehensive Vascular Program. This section and the referenced
appendices summarize the most significant to provide a fuller institutional context for further
planning.
INSTITUTIONAL STRATEGIC PRIORITIES
The UCDHS has set a goal to achieve ranking, within the decade, in the top quartile of U.S.
academic medical research institutions, as measured by extramural funding, reputation and
scientific impact on health care. Currently UCDHS has $103 million in annualized extramural
funding (total costs) and is ranked by the NIH 52nd out of 126 medical schools for extramural
funding.
UCDHS has for more than a decade, used a strategic planning process to regularly update its
institutional priorities and guide major investments. The current strategic plan, updated in 2004,
identifies Vascular Biology as one of four major focus areas in its research and clinical missions.
Appendix A. graphically presents the institution’s four focus areas, as well as common and
supporting scientific themes, approaches and infrastructure priorities.
CURRENT UCDHS FACULTY GRANTS IN AREAS RELATED TO VASCULAR BIOLOGY /
MEDICINE
Appendix B. lists active extramural grants to UCDHS faculty in the cardiovascular arena from
the NHLBI, other NIH institutes, and non-NIH sponsors. The list excludes UCD faculty outside
of the School of Medicine/UCDHS (e.g., Veterinary Medicine, College of Engineering, College of
Agriculture & Environmental Sciences and the Division of Biological Sciences) and at
collaborating institutions, such as the Lawrence Livermore National Laboratory, USDA Western
Human Nutrition Program, Children’s Hospital Oakland Research Institute (CHORI) and the VA
Northern California.
MAJOR GRANTS IN PREPARATION (PPG’s)
Dr. John Rutledge is leading the organization of a program project and an NIH Road Map
application with bearings on vascular biology. The PPG application is focused on studying
inflammation at the interface of blood and endothelium, specifically targeting the transition from
acute to chronic inflammation. The proposal has six co-investigators from the UCDHS (Drs. Lars
Berglund, F.E. Curry, J. Eiserch, I. Jialal, A. Knolwton, and A. Villablanca) and one from the
College of Engineering, Department of Biomedical Engineering (Dr. S. Simon). The NIH
Roadmap Initiative proposal (a translational research center for nanoscience and
nanotechnology) is focused on nanoscale lipid and protein interactions with vascular cells and is
a broadly collaborative effort with other campus units outside of the UCDHS.
Internal Medicine’s Division of Cardiovascular Medicine is in the very early planning stages of a
potential program project application in translational electrophysiology and congestive heart
failure. The effort is being organized by Drs. Reginald Low and Nipvan Chiamvimonvat.
POTENTIALLY COMPLEMENTARY RECRUITMENTS PLANNED BY DEPARTMENTS
The UCDHS has launched a new initiative in stem cell biology, led by the Departments of
Pathology and Cell Biology & Human Anatomy. Four FTE are available for recruitment, with
13
vascular applications of stem cells having been identified as one of two focus areas for
recruitment.
The Department of Internal Medicine has a proposal before the Health System to launch an
initiative in cardiovascular disease entitled “Personal Medicine, Population Health: Reducing the
Burden of Cardiovascular Disease in Individuals and the Communities.” The proposal, which is
currently being evaluated, proposes the recruitment of six individuals with four FTE. The new
hires are proposed to be split between a translational laboratory research unit and a health
services research unit.
Additional recruitments are taking place or planned in other departments, including Human
Physiology/Membrane Biology, Pharmacology (with an emphasis in the pharmacogenomics of
excitable membranes) and Biological Chemistry. Additional recruitments are underway in the
UCD Genome Center, some of which will be appointed to School of Medicine departments.
These recruits present an opportunity for joint or complementary recruitments with the vascular
research program.
ENDOWED CHAIRS
A new endowed chair is pending establishment for the research component of the
Comprehensive Vascular Program.
Other endowed chairs are pending in individual departments that potentially complement the
vascular research program.
Four current faculty with interests related to vascular biology/medicine (Drs. Iswarlal Jialal, John
Rutledge, Jason Eiserich, Sarah Yuan) hold endowed chairs or professorships.
14
ANTICIPATED RESOURCE REQUIREMENTS
Substantial, multi-million dollar investments are anticipated to develop the vision of the
Comprehensive Vascular Program. Many details regarding the scope and magnitude of these
resources are yet to be defined.
CLINICAL PROGRAM
The development of the clinical side of the program will require its own multi-million dollar
investment. Consultants Laird and Goldschmidt cited various needs (e.g., clinician recruits,
acute care/intensive care beds, expanded interventional/ catheterization labs, and a
multidisciplinary joint outpatient clinic). Such enhancements will require further evaluation and
discussion with potential candidates for clinical leadership.
RESEARCH PROGRAM
The program’s research component will similarly require a multi-million dollar investment,
including an appropriate allocation of FTE faculty positions, start-up funds, research laboratory
space, expanded large animal holding and procedure facilities, and other resources.
FTE: We anticipate a limited number of dedicated faculty FTE’s (to be negotiated) and one
endowed chair for the vascular research program. Other recruitments into the program will be
collaborative efforts with departments that have identified recruitments in vascular related areas.
Appropriate start-up funding will be negotiated.
Bench Laboratory Space: The conversion of the former clinical laboratories building in
Sacramento to bench research laboratory space (i.e., the Research III Building) in 2006 will
make available 12,456 assignable square feet (ASF) of useable research space. This space
consists of 7,692 ASF of labs, 2,122 ASF of research core/equipment space and 2,651 of
office/conference space. Approximately $2 million will be invested in these laboratory
conversion/renovations. We anticipate that a portion of this space will be occupied by some
existing UCDHS vascular faculty to help quickly nucleate the program. Additional space may
become available after the initial launch phase, as justified by the success of the initiative.
Although UCDHS has a substantial number of vascular researchers, their laboratories are
presently geographically dispersed, which presents an obstacle to collaboration and program
identity. Locating the basic research labs of the program in Sacramento also will foster
translational research and interactions with clinicians. Appendix C. shows the location of
Research II relative to other research and clinical facilities at the UC Davis Medical Center
campus.
Large Animal Facilities: To support translational studies, we anticipate the completion of a
large animal procedure room and temporary holding space for large animals within an existing
vivarium in the Research III Building in Sacramento. The space will accommodate research on
new interventional techniques involving catheters, stents, stent-delivered drugs, growth factors,
stem cells, anti-inflammatory agents and other approaches suggested by basic investigations.
Existing large animal procedure and holding space is immediately available on the main Davis
campus at the Center for Laboratory Animal Services. Investments in additional imaging
equipment for acute procedures (e.g. angiography) are expected for both the Sacramento and
Davis large animal facilities.
15
Clinical Research: Clinical research activities may substantially benefit from linkages to new
clinical research support initiatives at the UCDHS. These include the recently opened UCD
General Clinical Research Center at the Northern California VA Hospital in Sacramento and the
newly launched Clinical Research Investigator Support Program (CRISP) at UCDMC. The latter
provides “one-stop shopping” for a menu of research support services including support for
bioinformatics, database management, IRBs, clinical trials support and grant writing.
16
APPENDIX A.
Research Mission Strategy
Research Mission Strategy:
Common Themes:
Geriatrics Research
Cross-Cultural Research
Women Health Research
Approaches:
Special Themes:
Cancer
Membrane
Biology
Neuroscience
Health Services
Research
Genomics
Multidisciplinary
Research
Biostats /
Data Management
Infectious
Disease
VA/Shriners/LLL
Partnerships
Vascular
Biology
Stem Cell
Program
Campus
Partnerships
PPG / Collaborative
Grants
Infrastructure:
Mouse Primate Academic IS
Research Clinical Trials
Biology Center Telemedicine
Quality
Office /
Informatics Compliance
CRISP
Imaging
Center
GCRC
Faculty &
Staff
Development
Clinical Mission Strategy
Clinical Mission Strategy:
Common Themes:
Geriatrics/ Health Aging
Cross-Cultural Competence
Approaches:
Special Themes:
Emergency and
Trauma Services
Community
Safety Net Care
Health System
Financial
Viability
Women & Children’s Services
Cancer
Neuroscience
Multidisciplinary
Care Teams
Infectious
Disease
Performance /Quality
Management
Clinical D-Line
Financials / EMR
Community Partners
Vascular
Biology
VA / Shriners
Partnerships
Outcomes Assessment
Infrastructure:
Children’s Contracting /
Hospital
MSO
Management
Hospital / Clinic
Access
(Beds, ORs & Clinics)
Compliance /
Accreditation
PCN
Outreach/
Telehealth
Faculty &
Staff
Development
17
APPENDIX B.
NIH EXTRAMURAL AWARDS – NHLB & OTHER VASCULAR -- UCDHS FACULTY
PI
Dept
Agency
ID#
AN TC$
Award Type
Grant Type
Beaman, Blaine
MED MICROBIOLOGY
NIH 5 R01 HL69426-03
$294,640
Continuation
Grant
BERGLUND, LARS
INTERNAL MEDICINE
NIH 7 R01 HL65938-04
$257,874
Continuation
Grant
BERGLUND, LARS
INTERNAL MEDICINE
NIH 7 r01 hl062705-04
$1
No Cost Ext
Grant
BONHAM, ANN
PHARMACOLOGY
NIH 2 R01 HL60560-04
$222,750
Renewal
Grant
BONHAM, ANN
PHARMACOLOGY
NIH 5 R01 HL67183-04
$371,250
Continuation
Grant
CALA, PETER
HUMAN PHYSIOLOGY
NIH 5 R37 HL21179-26
$584,688
Continuation
Grant
CHEUNG, ANTHONY
PATHOLOGY
NIH 5 R01 HL67432-03
$329,387
Continuation
Grant
CHEW, HELEN
CHIAMVIMONVAT, NIPAVAN
INTERNAL MEDICINE
INTERNAL MEDICINE
NIH 1 r03 ca99527-02
NIH 5 R01 HL68507-04
$74,250
$259,875
Continuation
Continuation
Grant
Grant
CHIAMVIMONVAT, NIPAVAN
CURRY, FITZ-ROY
CURRY, FITZ-ROY
INTERNAL MEDICINE
HUMAN PHYSIOLOGY
HUMAN PHYSIOLOGY
NIH 5 R01 HL67737-03
NIH 5 R01 HL44485-12
NIH 5 R37 HL28607-22
$1
$438,995
$297,000
No Cost Ext
Continuation
Continuation
Grant
Grant
Grant
DOUGLAS, GORDON
CELL BIO & HUM ANAT
NIH 1 R01 HL68035-01A2
$360,095
Revision
Grant
ELLIS, WILLIAM
PATHOLOGY
NIH/ USC 2 P01 AG12435-09
$63,470
New
Subcontract
JAGUST, WILLIAM
NEUROLOGY
NIH/ USC 2 P01 AG12435-09
$198,954
New
Subcontract
JUE, THOMAS
KAPPAGODA, CHULANI
BIOLOGICAL CHEM
INTERNAL MEDICINE
NIH 5 R01 EB002038-04 (previously 5 R01
$1 GM58688)
No Cost Ext
NIH 5 R01 HL62471-04
$222,750
Continuation
Grant
Grant
KAUFMAN, MARC
INTERNAL MEDICINE
NIH 5 R01 HL064125-04
$297,000
Continuation
Grant
KAUFMAN, MARC
INTERNAL MEDICINE
NIH 5 r01 hl30710-20
$334,125
Continuation
Grant
KNOWLTON, ANNE
INTERNAL MEDICINE
NIH 7 R01 AG19327-03
$215,740
Continuation
Grant
MUNGAS, DAN
NEUROLOGY
NIH/ USC 5 P01 AG12435-09
$67,461
O’DONNELL, MARTHA
HUMAN PHYSIOLOGY
NIH 1 R01 NS39953-02
$282,150
Continuation
REED, BRUCE
ROBBINS, JOHN
NEUROLOGY
INTERNAL MEDICINE
NIH/ USC 2 P01 AG12435-09
NIH N01-WH-3-2113
$232,201
$965,341
New
New (Amend 18)
ROBBINS, JOHN
INTERNAL MEDICINE
NIH n01-hc-85083
$173,309
Renewal (Amend 34)
Contract
ROBBINS, JOHN
ROBBINS, JOHN
INTERNAL MEDICINE
INTERNAL MEDICINE
NIH N01-HC-85083
NIH 5 U01 HL53916-10
$14,493
$175,326
Supplement
Continuation
Contract
Grant
RUTLEDGE, JOHN
INTERNAL MEDICINE
NIH 5 R01 HL71488-02
$327,682
Continuation
Grant
RUTLEDGE, JOHN
INTERNAL MEDICINE
NIH 5 r01 hl55667-08
$294,623
Revision
Grant
TARANTAL, ALICE
PEDIATRICS
NIH 1 R13 HL072168-02
$15,000
Continuation
Grant
TARANTAL, ALICE
PEDIATRICS
NIH 5 R01 HL069748-03
$562,169
Continuation
Grant
TARANTAL, ALICE
PEDIATRICS
NIH 5 R01 HL069748-03S1
$59,650
Supplement
Grant
VILLABLANCA, AMPARO
INTERNAL MEDICINE
NIH 5 K01 HL04142-05
TOTAL ANNUAL TC $
$136,687
$8,128,938
Continuation
Grant
New
Subcontract
Grant
Subcontract
Grant
Title
MECHANISMS OF HOMEOSTASIS AND REPAIR IN THE
LUNG
LIPOPROTEIN AND ADIPOSE TISSUE METABOLISM IN HIV
STUDY OF LIPOPROTEIN (A) METABOLISM IN NORMAL
HUMAN VOLUNTEERS
METABOTROPIC GLUTAMATE RECEPTORS AND
BARORECEPTOR INPUT
POST EXERCISE HYPOTENSION: CENTRAL SITES AND
MECHANISMS
FUNDAMENTAL AND FUNCTIONAL ASPECTS OF NA/H
EXCHANGE
BIOENGINEERING METHODS TO STUDY BLOOD
SUBSTITUTES
VENOUS THROMBOEMBOLISM AMONG CALIFORNIA
CANCER PATIENTS
REGULATION OF CARDIAC ION CHANNELS
REGIONS OF NA CHANNEL INVOLVED IN PERMEATION
AND GATING
NEW APPROACH TO ENDOTHELIAL CLEFT STRUCTURE
TRANSPORT ACROSS CAPILLARY ENDOTHELIUM
FLOW EFFECTS ON ENDOTHELIAL / TROPHOBLAST
INTERACTION
AGING BRAIN: VASCULATURE, ISHEMIA, BEHAVIOR CORE C
AGING BRAIN: VASCULAR, ISCHEMIA AND BEHAVIOR CORE A
LIMITATION TO OXIDATIVE PHOSPHORYLATION IN
MYOCARDIUM
REFLEXES IN LEFT VENTRICULAR DYSFUNCTION
ESTROGEN EFFECTS ON CARDIOVASCULAR RESPONSE
TO EXERCISE
METABOLITE EFFECTS OF GROUP III AND IV MUSCLE
AFFERENTS
AGING, ESTROGEN, HSPS AND MYOCARDIAL ISCHEMIA
VASCULAR AND DEGENERATIVE CONTRIBUTIONS TO
DEMENTIA: PROJ 5
BLOOD-BRAIN BARRIER CATION-CHLORIDE
COTRANSPORT IN CEREBRAL ISCHEMIA
PROJECT 1: LONGITUDINAL PET, LACUNES, COGNITION
AND BEHAVIOR THE AGING BRAIN: VASCLATURE,
ISCHEMIA AND BEHAVIOR
WOMEN'S HEALTH INITIATIVE
CARDIOVASCULAR HEALTH STUDY-MORBIDITY AND
MORTALITY FOLLOW-UP FIELD CENTER
CARDIOVASCULAR HEALTH STUDY - MORBIDITY AND
MORTALITY FOLLOW-UP FIELD CTR
SLEEP HEART HEALTH STUDY
EFFECTS OF A HIGH GLYCEMIC LOAD DIET ON THE
VASCULAR SYSTEM
INTERACTION OF LIPOPROTEINS WITH THE VASCULAR
WALL
ANNUAL GENE THERAPY SYMPOSIUM FOR LUNG AND
BLOOD DISEASES
CTR FOR FETAL MONKEY GENE TRANSFER FOR HLB
DISEASES
CTR FOR FETAL MONKEY GENE TRANSFER FOR HLB
DISEASES
GENETIC MECHANISMS OF ESTROGEN
ATHEROPROTECTION
18
APPENDIX B. (CONTINUED)
PRIVATE EXTRAMURAL AWARDS – VASCULAR -- UCDHS FACULTY
PI
Dept
Agency
ID#
AN TC$
Award Type
AMSTERDAM, EZRA
INTERNAL MEDICINE
ASTRA ZENECA PHARM
$9,837
New
AMSTERDAM, EZRA
INTERNAL MEDICINE
SCIOS INC
7065
$20,048
New
BOMMER, WILLIAM
INTERNAL MEDICINE
BOEHRINGER INGELHEIM
6288
$61,854
New
CHEUNG, ANTHONY
PATHOLOGY
CERUS CORP 11840
$63,563
New
DAWSON, DAVID
SURGERY
UNITED THERAPEUTICS
10653
$42,914
New
DEVARAJ, SRIDEVI
PATHOLOGY
AM DIABETES7867
ASSOC
$137,968
New
ONTARGET: ONGOING TELMISARTAN ALONE AND IN
COMBINATION WITH RAMIPRIL GLOBAL ENDPOINT TRIAL
Clinical Drug Study
EFFECTS OF POLYETHYLENE GLYCOL HAMSTER RED
BLOOD CELLS ON THE MICROCIRCULATION
Contract
A RANDOMIZED, PLACEBO CONTROLLED, 12 WEEK
MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF
REMODULIN IN PATIENTS WITH CRITICAL LIMB
ISCHEMIA FOLLOWING AN AUTOGENOUS VEIN
INFRAINGUINAL BYPASS GRAFT
Clinical Drug Study
MECHANISMS OF MONOCYTE PROATHEROGENICITY IN
DIABETIC VASCULAR DISEASE
Grant
$75,000
New
$174,335
New
$45,178
New
Contract
PATHOLOGY
THE BEVERAGE INST FOR HEALTH & WELLNESS
$167,954
New
GLASER, NICOLE
PEDIATRICS
AM DIABETES4010
ASSOC
$99,995
New
GLATTER, KATHRYN
INTERNAL MEDICINE
AM HEART ASSOC
0265312Y
$60,000
New
GLATTER, KATHRYN
INTERNAL MEDICINE
PFIZER SCHOLARS
$65,000
New
GLATTER, KATHRYN
HAGIWARA, NOBUKO
INTERNAL MEDICINE
INTERNAL MEDICINE
st jude med res ctr
AM HEART ASSOC
0365010y
$1,244
$70,000
New
New
HAGIWARA, NOBUKO
INTERNAL MEDICINE
MARCH OF DIMES
5-FY03-159
BIRTH DEFECTS
010404
JIALAL, ISHWARLAL
PATHOLOGY
JUVENILE DIABETES
7793 RES FOUND
KAPPAGODA, CHULANI
INTERNAL MEDICINE
POLYPHENOTICS
KASIM-KARAKAS, SIDIKA
KAYSEN, GEORGE
INTERNAL MEDICINE
INTERNAL MEDICINE
CALIF DAIRY 12133
RES FOUND
DIALYSIS CLINIC
009493 S-1419
LOW, REGINALD
INTERNAL MEDICINE
BERLEX LAB
LOW, REGINALD
INTERNAL MEDICINE
BOSTON SCIENTIFIC
LOW, REGINALD
INTERNAL MEDICINE
BOSTON SCIENTIFIC
LOW, REGINALD
INTERNAL MEDICINE
LOW, REGINALD
LOW, REGINALD
$93,543
$122,875
9277
Title
LUNAR: A 12 WEEK, RANDOMIZED, OPEN LABEL, 3 ARM,
PARALLEL GROUP, MULTICENTER, PHASE IIIB STUDY
COMPARING THE EFFICACY AND SAFETY OF
ROSUVASTATIN 20MG AND 40MG WITH THAT OF
ATORVASTATIN 80MG IN SUBJECTS WITH ACUTE
CORONARY SYNDROMES
Clinical Drug Study
ADHERE: ACUTE DECOMPENSATED HEART FAILURE
REGISTRY
Clinical Drug Study
A SINGLE CTR DOUBLE BLIND STUDY ON THE EFFECTS
OF FORTIFIED REDUCED CALORIE ORANGE JUICE ON
LIPID PROFILE IN HEALTHY HUMAN VOLUNTEERS
Contract
CEREBRAL ISCHEMIA AND CEREBRAL EDEMA IN
CHILDREN WITH DIABETIC KETOACIDOSIS
Grant
RISK OF SUDDEN DEATH IN CONGENITAL LONG QT
SYNDROME
Grant
RISK OF SUDDEN CARDIAC DEATH IN FEMALES WITH
LONG QT SYNDROME: INTERACTION BETWEEN CARDIAC
REPOLARIZATION AND FEMALE GENDER
Grant
does af suppression pacing promote reverse electrical
remodeling of the atria? (01-08-007)
Clinical Drug Study
A MOUSE MODEL FOR NEONATAL MYOPATHY
Grant
A MOUSE MODEL FOR NEONATAL CARDIOSKELETAL
MYOPATHY
Grant
MONOCYTE FUNCTION AND INFLAMMATION IN TYPE 1
DIABETES AND ITS MODULATION
Grant
DEVARAJ, SRIDEVI
6190
Grant Type
New
Revision
$22,987
New
$4,962
New
9044
$12,770
New
BOSTON SCIENTIFIC SCIMED
6976
$11,550
New
INTERNAL MEDICINE
INNERCOOL THERAPIES
8741
$9,140
New
INTERNAL MEDICINE
INTRALUMINAL THERAPEUTICS 7930
$1,610
New
EFFECT OF GRAPE SEED EXRACT ON PLATELET FUNCTION
EFFECTS OF WHEY PROTEIN ON WEIGHT LOSS, GLUCOSE
AND LIPID METABOLISM IN OBESE WOMEN WITH
INSULIN RESISTANCE AND POLYCYSTIC OVARY
SYNDROME
Grant
LIPID DISORDERS IN THE NEPHROTIC SYNDROME
Grant
A MULTICENTER, RANDOMIZED, DOUBLE BLIND,
PLACEBO CONTROLLED STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF AD5FGF-4 IN PATIENTS WITH
STABLE ANGINA
Clinical Drug Study
ARRIVE TAXUS PERI-APPROVAL REGISTRY: A TWO
PHASED, MULTICENTER SAFETY SURVEILLANCE PROG
Device
TAXUS V: A RANDOMIZED, DOUBLE BLIND TRIAL TO
ASSESS TAXUS PACLITAXEL-ELUTING CORONARY
STENTS, SLOW-RELEASE FORMULATION
Clinical Drug Study
TAXUS IV-SR: TREATMENT OF DE NOVO CORONARY
DISEASE USING A SINGLE PACLITAXEL-ELUTING STENT
Clinical Drug Study
INTRAVASCULAR COOLING ADJUNCTIVE TO
PERCUTANEOUS CORONARY INTERVENTION (ICE-IT)
Device
GREAT: GUIDED RADIO FREQUENCY ENERGY ABLATION
OF TOTAL OCCLUSIONS
Device
19
APPENDIX B. (CONTINUED)
PRIVATE EXTRAMURAL AWARDS – VASCULAR -- UCDHS FACULTY
PI
Dept
Agency
ID#
AN TC$
Award Type
O'DONNELL, MARTHA
HUMAN PHYSIOLOGY
PHILIP MORRIS
3314
usa, inc
$235,046
New
RUTLEDGE, JOHN
INTERNAL MEDICINE
BIOSTAR
9296
$169,851
New
RUTLEDGE, JOHN
INTERNAL MEDICINE
the nora eccles
11267
treadwell found
$375,000
New
SCHAEFER, SAUL
INTERNAL MEDICINE
AM HEART ASSOC
5290
$71,500
New
SCHAEFER, SAUL
INTERNAL MEDICINE
PHILIP MORRIS USA, INC
5464
$150,356
New
STYNE, DENNIS
PEDIATRICS
NOVO NORDISK PHARM
VALENTE, RICHARD
INTERNAL MEDICINE
BRIGHAM & WOMEN'S HOSP/ BRISTOL
3006 MYERS
$9,838
SQUIBB
VALENTE, RICHARD
INTERNAL MEDICINE
SANOFI-SYNTHELABO RES
VALENTE, RICHARD
INTERNAL MEDICINE
TIMI3 SYSTEMS
VERRO, PIERO
NEUROLOGY
NOVARTIS PHARM
10496
WANG, SAMUEL
INTERNAL MEDICINE
BIOTRONIK
WANG, SAMUEL
INTERNAL MEDICINE
GUIDENT CORP
WEISS, ROBERT
INTERNAL MEDICINE
PHILIP MORRIS
8043
USA, INC
WHITE, RICHARD
INTERNAL MEDICINE
ASTRA ZENECA
9007
$26,500
New
New (Amend 1)
Grant Type
Title
BRAIN MICROVESSEL CATION-CHLORIDE COTRANSPORT
IN CEREBRAL ISCHEMIA
DISCOVERY OF CHEMOKINE RECEPTORS IN VASCULAR
INFLAMMATION
Grant
portfolio of research grants in diabetes, cardiovascular
disease and arthritis
Grant
REGULATION OF MITOCHONDRIAL CALCIUM DURING
ISCHEMIA/ REPERFUSION
Grant
REGULATION OF MITOCHONDRIAL CALCIUM DURING
ISCHEMIA REPERFUSION
Grant
BASAL/ BOLUS THERAPY WITH INSULIN ASPART
(NOVOLOG) VERSUS REGULAR HUMAN INSULIN OR
INSULIN LISPRO IN COMBINATION WITH NPH: AN OPEN
LABEL, RANDOMIZED, PARALLEL GROUP, MULTICENTER
STUDY IN CHILDREN AND ADOLESCENTS WITH TYPE 1
DIABETES
Clinical Drug Study
PROVE IT: PRAVASTATIN OR ATORVASTATIN
Subcontract EVALUATION AND INFECTION THERAPY
AN INTERNATIONAL RANDOMIZED DOUBLE BLIND STUDY
EVALUATING THE EFFICACY AND SAFETY OF
FONDAPARINUX VERSUS ENOXAPARIN IN THE ACUTE
TREATMENT OF UNSTABLE ANGINA/NON-ST-SEGMENT
ELEVATION MI ACUTE CORONARY SYNDROMES (OASIS5)
Clinical Drug Study
Grant
10164
$15,572
New
7473
$4,230
New
$153,724
New
PLUS PERFUSION BY THROMBOLYTIC AND ULTRASOUND
Clinical Drug Study
A 24 WEEK PROSPECTIVE, RANDOMIZED, MULTICENTER,
DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL
GROUP COMPARISON OF THE EFFICACY, TOLERABILITY
AND SAFETY OF 3-12 MG/DAY OF EXETON
(RIVASTIGMINE) CAPSULES IN PATIENTS WITH
PROBABLE VASCULAR DEMENTIA
Clinical Drug Study
9279
$1,210
New
BIOTRONIK HOME MONITORING TECHNOLOGY FOR
IMPLANTABLE CARDOVERTER DEFIBRILLATOR THERAPY
WIRELESS, AUTOMATIC, MOBILE MONITORING FOR ICDS
Clinical Drug Study
10071
$1,856
New
Contract
$133,333
$40,000
Revision
New
Grant
Contract
ARRHYTHMIA SINGLE SHOCK DFT VERSUS ULV: RISK
REDUCTION EVAL WITH ICD IMPLANTATIONS (ASSURE)
THE ROLE OF P73 IN VASCULAR DISEASE AND
ATHEROSCLEROSIS
RISK STRATIFICATION OF CANCER POPULATIONS FOR
VENOUS THROMBOEMBOLISM
WHITE, RICHARD
INTERNAL MEDICINE
NOVARTIS PHARM
6174
$30,789
New (Amend 1)
WHITE, RICHARD
INTERNAL MEDICINE
SANOFI SYNTHELABO
$28,975
New
A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTI-CENTER STUDY OF THE EFFICACY
AND SAFETY OF LONG TERM ADMINISTRATION OF
NATEGLINIDE AND VALSARTAN IN THE PREVENTION OF
DIABETES AND CARDIOVASCULAR OUTCOMES IN
SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE (I
Clinical Drug Study
A PARALLEL RANDOMIZED CONTROLLED EVALUATION OF
CLOPIDOGREL PLUS ASPIRIN, WITH FACTORIAL
EVALUATION OF IRBESARTAN, FOR THE PREVENTION OF
VASCULAR EVENTS, IN PATIENTS WITH ATRIAL
FIBRILLATION
Clinical Drug Study
New
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND,
PARALLEL GROUP TRIAL TO DEMONSTRATE THE
EFFICACY OF FONDAPARINUX SODIUM IN ASSOCIATION
WITH INTERMITTENT PNEUMATIC COMPRESSION VERSUS
INTERMITTENT PNEUMATIC COMPRESSION USED ALONE
FOR THE PREVENTION OF VENOUS THROM
Clinical Drug Study
WHITE, RICHARD
INTERNAL MEDICINE
SANOFI-SYNTHELABO
6178
TOTAL ANNUAL TC $
$49,665
$2,871,772
20
APPENDIX C. UC DAVIS MEDICAL CENTER CAMPUS FACILITIES
UC Davis Medical Center
Shriner’s Hospital &
Research Labs
Main Hospital
Complex
UCD GCRC
at VA Hospital
Cancer Center
Imaging Research
Center
Research Buildings
Conversion of Clinical Labs
To Research II (Vascular )
Adjacent off-site research
Biophotonics Center
Ambulatory Care Center
& Clinical Trials Office
M.I.N.D. Institute
Construction Site
21